News & Announcements
-
IB Software Enhances Clinical Decision-Making
/**/ RNS Number : 8182O IQ-AI Limited 17 May 2024 May 17, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Software Enhances Clinical Decision-Making at Insel Gruppe AG Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces the successful deployment of its state-of-the-art software…
-
Rare Pediatric Disease Designation Granted to GaM
/**/ RNS Number : 9596N IQ-AI Limited 10 May 2024 May 10, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces U.S. FDA Rare Pediatric Disease Designation Granted to GaM For the Treatment of atypical teratoid rhabdoid tumor (“ATRT”) Further to the announcement made on 8 November 2023, Imaging Biometrics (“IB”),…
-
IB Announces Expanded Access Program for GaM
/**/ RNS Number : 0442N IQ-AI Limited 02 May 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Expanded Access Program for Oral Gallium Maltolate Company initiating program based on phase 1 tolerability and safety results Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has received…
-
Publication of Annual Report
/**/ RNS Number : 4602M IQ-AI Limited 29 April 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Publication of Annual Report The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2023. The Annual Report will be available on the Company’s corporate website…
-
Grant of Options
/**/ RNS Number : 5260F IQ-AI Limited 05 March 2024 IQ-AI Limited (“IQ-AI” or the “Company”) Grant of Options IQAI Limited (the “Company” or “IQAI”), announces that, the Company has granted options over a total of 18,905,474 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) to the Directors and employees to the…